Clinical trial
A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone…
NCT00321464 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00321464 |
|---|---|
| Title | A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects. |
| Official title | A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Subjects With Advanced Breast Cancer |
| Lead sponsor | Amgen, Industry |
| Collaborators | Daiichi Sankyo Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Bone Metastases |
| Intervention type | Biological, Drug |
| Interventions | Denosumab, Zoledronic Acid |
| Enrollment | 2,049 |
| Start date | Apr 1, 2006 |
| Primary completion | Jul 20, 2009 |
| Completion | Apr 4, 2012 |
| First posted | May 3, 2006 |
| Last update posted | Nov 8, 2022 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: